Synergistic Antimicrobial Prophylaxis Systems
Legal Citation
Summary of the Inventive Concept
The present invention relates to novel synergistic combinations of peptides derived from Acinetobacter baumannii with distinct technologies such as AI, IoT, blockchain, and new materials to create more powerful systems for personalized antimicrobial prophylaxis and therapy.
Background and Problem Solved
The original patent disclosed peptides derived from Acinetobacter baumannii for vaccination, but it had limitations in terms of personalized approaches, real-time monitoring, and tracking efficacy. The new inventive concept addresses these limitations by integrating the patented peptides with other distinct technologies to create more effective and personalized systems.
Detailed Description of the Inventive Concept
The synergistic combinations disclosed herein integrate the peptides derived from Acinetobacter baumannii with AI-powered diagnostic modules for identifying specific microbial strains, IoT-enabled sensors for real-time monitoring of immune responses, blockchain-based tracking systems for monitoring vaccination efficacy, and novel materials such as graphene-based adjuvants and nanotechnology-enabled delivery systems. These combinations enable personalized antimicrobial prophylaxis and therapy, real-time monitoring, and tracking of vaccination efficacy.
Novelty and Inventive Step
The new claims are novel and non-obvious as they combine the peptides derived from Acinetobacter baumannii with distinct technologies to create synergistic systems that are more effective and personalized than the original patent. The integration of these technologies provides a new and inventive approach to antimicrobial prophylaxis and therapy.
Alternative Embodiments and Variations
Alternative embodiments of the inventive concept include the use of different AI algorithms, IoT sensors, blockchain platforms, and novel materials. Variations of the inventive concept could include the integration of additional technologies such as machine learning, genomics analysis, and biometrics.
Potential Commercial Applications and Market
The inventive concept has significant commercial potential in the fields of antimicrobial prophylaxis and therapy, personalized medicine, and digital health. The target market includes pharmaceutical companies, biotech companies, and healthcare providers.
CPC Classifications
| Section | Class | Group |
|---|---|---|
| A | A61 | A61K39/104 |
| C | C07 | C07K14/212 |
| A | A61 | A61K2039/543 |
| A | A61 | A61K2039/55505 |
| A | A61 | A61K2039/55566 |
| G | G01 | G01N2333/22 |
| G | G01 | G01N2469/20 |
Section 103 Obviousness Analysis (PHOSITA)
Field of Art
Biotechnology and Immunology, specifically focused on antimicrobial peptide development, vaccine design, and advanced diagnostic technologies involving Acinetobacter baumannii research
Person of Ordinary Skill (PHOSITA) Profile
A skilled practitioner with advanced degrees in microbiology, immunology, or bioengineering, possessing expertise in peptide engineering, vaccine development, and emerging technologies like AI, IoT, and nanotechnology
Obviousness Rationale
A PHOSITA would recognize that integrating advanced diagnostic and tracking technologies with existing antimicrobial peptide research represents a predictable extension of known vaccine development strategies. The combination of AI-powered diagnostics, IoT monitoring, and novel delivery systems with established peptide technologies follows a logical progression of personalized medicine approaches. The technical variations disclosed in the PTD represent incremental improvements that would be obvious to a skilled researcher seeking to enhance vaccine efficacy and monitoring.
Obvious Combinations & Variations
Original Patent Information
| Patent Number | US 11,857,615 |
|---|---|
| Title | Peptides derived from Acinetobacter baumannii and their use in vaccination |
| Assignee(s) | Evaxion Biotech A/S |